Probably the best risk reward junior biotech, dare I say, in the world at the moment. $10m EV and fully funded for its pivotal P3 trial in the EU. I'm not too concerned about the possibility of having to do P3 in EU first, get registration and start selling there first then come back to the US with real-world data. Reality is this company won't be a $40m mkt cap in the lead up to its P3 read out, more like a $400m mkt cap, that's the play.
Ann: Invex Receives Written Response from FDA on Type C Meeting, page-51
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.885M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 49728 | 6.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.7¢ | 7950 | 1 |
View Market Depth
| Last trade - 15.50pm 03/07/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable